Human Brunello kinome pooled library, guides 1-4 in lentiCRISPRv2 backbone Citations (8)
Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437. PubMed Journal
Articles Citing Human Brunello kinome pooled library, guides 1-4 in lentiCRISPRv2 backbone
| Articles |
|---|
| Next-Generation Sequencing of Genome-Wide CRISPR Screens. Yau EH, Rana TM. Methods Mol Biol. 2018;1712:203-216. doi: 10.1007/978-1-4939-7514-3_13. PubMed |
| CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, Schmid RA, Peng RW. Mol Cancer Ther. 2020 Feb;19(2):661-672. doi: 10.1158/1535-7163.MCT-19-0724. Epub 2019 Nov 6. PubMed |
| Applying CRISPR Screen in Diabetes Research. Yi P, Morrow N. Diabetes. 2021 Sep;70(9):1962-1969. doi: 10.2337/dbi20-0047. Epub 2021 Jun 23. PubMed |
| Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. He MY, Halford MM, Liu R, Roy JP, Grant ZL, Coultas L, Thio N, Gilan O, Chan YC, Dawson MA, Achen MG, Stacker SA. Commun Biol. 2021 Jul 15;4(1):878. doi: 10.1038/s42003-021-02397-3. PubMed |
Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures.
Hu M, Lei XY, Larson JD, McAlonis M, Ford K, McDonald D, Mach K, Rusert JM, Wechsler-Reya RJ, Mali P.
Biomaterials. 2022 Jan;280:121276. doi: 10.1016/j.biomaterials.2021.121276. Epub 2021 Dec 2.
PubMed
Associated Plasmids |
| Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. Cao Y, Cheng C, Yin Y, Yee SN, Zheng Y, Mahapatra S, Paturu R, Coleski A, VanAken S, Yang F, Pakkan R, Zhao Y, Bhattacharyya R, Miner SJ, Cao X, Mannan R, Li C, Sahai V, Ding K, Lyssiotis CA, Chinnaiyan AM, Qiao Y. Cell Rep Med. 2026 Apr 21;7(4):102695. doi: 10.1016/j.xcrm.2026.102695. Epub 2026 Mar 24. PubMed |
| CRISPR screening identifies TRIM27 as a destabilizer of the Smith-Magenis syndrome protein RAI1. Lin YC, Lee YJ, Li CX, Chang HC, Kowalczyk M, Haque M, Dragoiescu A, Losier TT, Taylor JA, Rousseaux MWC, Huang WH. Genetics. 2026 Jul 6;233(3):iyag121. doi: 10.1093/genetics/iyag121. PubMed |
| MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening. Yoshino H, Fukuda I, Enokida H, Seki N, Goto Y. Genes (Basel). 2026 Jul 12;17(7):789. doi: 10.3390/genes17070789. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.